Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SABBOBCATon Oct 13, 2022 9:59am
143 Views
Post# 35022028

RE:RE:Expectations too high. Reset your animus.

RE:RE:Expectations too high. Reset your animus.

I got the vibe that they do have some news but arent willing to share it at this time. Maybe they are talking to the FDA about an amendment? or have already submitted information on advaning to a P2 and want to wait for a response? Who knows, but it is not surprising to me as the annual option grants are coming up... no need to get Mr Market all riled up before management gets their cheap options... 

 

 

SPCEO1 wrote: For me, the fact that five months into the phase 1b and they still have not seen two signs of efficacy is not a favorable sign. If TH-1902 works as expected it should have delivered 2 efficacious results  in one cancer type by now unless enrollment is really bad. And maybe it is really bad since they would not talk about it. 

Overall, the call was a dud and lacked the energy we saw in the Q2 call. If they wanted to pass along good vibes about TH-1902 in phase 1b, they could have found a way to do so, but instead they seemingly wanted to talk about almost anything else.  
 

Wino115 wrote: What was to be expected, frankly. They alway said they'd talk efficacy when it was scientifically proven with two or more patients.  We can assume, that is still the case.  

My hopes were for more quantitative facts on enrollment, survival, etc... We didn't get that. But we did get a rough estimate. We are 5 months in and they said the are on "pace" for full enrollment at worse in 5 more months.  The implication is that they are likely around 50% at this point. I would guess part of the issue is what we already know --these patients are at the very end of life and need to survive long enough for any therapy to work throught.  

But my guess is they are probably dosing around 25 or so patients at this point. 




<< Previous
Bullboard Posts
Next >>